Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis. (23rd June 2020)

• Record Type: Journal Article
• Authors: Deng, Jiawen; Silver, Zachary; Huang, Emma; Zheng, Elena; Kavanagh, Kyra; Wen, Aaron; Cheng, Wei; Dobransky, Johanna; Sanger, Stephanie; Grammatopoulos, George
• Is Part Of: Rheumatology. Volume 60:Number 2(2021)
• Page Start: 649
• Page End: 657
• Publication Date: 2020-06-23
• Subjects: glucocorticoid-induced osteoporosis -- bone loss -- fractures -- antiosteoporotic interventions -- network meta-analysis; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/keaa228
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Objective: To perform a network meta-analysis (NMA) on the efficacy of antiosteoporotic interventions in the prevention of vertebral and non-vertebral fractures in adult patients taking glucocorticoids (GCs). Methods: We performed NMAs based on a prospectively developed protocol. A librarian-assisted database search of MEDLINE, EMBASE, Web of Science, Cumulative Index of Nursing and Allied Health Literature (CINAHL), the Cochrane Central Register of Controlled Trials (CENTRAL) and Chinese databases was conducted for randomized controlled trials (RCTs) comparing antiosteoporotic interventions in adult patients taking GCs. Outcomes were vertebral and non-vertebral fracture incidences. Results: We included 56 RCTs containing 6479 eligible patients in our analysis. We found that alendronate and teriparatide were associated with decreased odds of both vertebral and non-vertebral fractures. Denosumab and risedronate were associated with decreased odds of vertebral fractures, while etidronate, ibandronate and alfacalcidol were associated with decreased odds of non-vertebral fractures. We observed low network heterogeneity as indicated by the I 2 statistic, and we did not detect evidence of publication bias. All outcomes were based on a moderate quality of evidence according to GRADE. Conclusion: Bisphosphonates, teriparatide and denosumab are associated with decreased odds of fracture in patients undergoing GC therapy. Vitamin D metabolites and analogues (e.g. alfacalcidol) may have greater anti-fracture efficacy compared with plain vitamin D. Systematic Review Registration: The International Prospective Register of Systematic Reviews (PROSPERO)—CRD42019127073